Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087074 · ClinicalTrials.gov registry record · Phase 2
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00087074 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants, below the 84-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00087074, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well CCI-779 works in treating patients with soft tissue sarcoma or gastrointestinal stromal tumor. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG temsirolimus
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087074
The ClinicalTrials.gov registry entry for NCT00087074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (35% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00087074 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00087074 about?
NCT00087074 is a clinical study titled "CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor". This phase II trial is studying how well CCI-779 works in treating patients with soft tissue sarcoma or gastrointestinal stromal tumor. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00087074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2004-06.
What conditions does trial NCT00087074 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Stage IV Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma.
What interventions are being tested in trial NCT00087074?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00087074?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087074 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
-
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Adult Soft Tissue Sarcoma
All registered trials for this condition
Gastrointestinal Stromal Tumor
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.